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Introduction: Transoesophageal endoscopic ultrasound with fine-
needle aspiration (EUS-FNA) is a minimally invasive procedure to
demonstrate unresectability in lung cancer patients with enlarged
malignant mediastinal lymph nodes (MLN). We compared the
performance of EUS-FNA to show malignant invasion in enlarged
versus small MLN.
Methods: A single center analysis was performed in lung cancer
patients with a suspicion for malignant MLN invasion based on the
available imaging. In these patients, EUS-FNA was presumed to
impact the diagnostic course since patients underwent surgical-
pathologic verification only when EUS-FNA did not demonstrate
MLN invasion.
Results: We evaluated 100 lung cancer patients in whom MLN
invasion was presumed based on the available imaging. In 75
patients (75%), there was at least one enlarged MLN, whereas in 25
patients (25%), only small MLN were found. The sensitivity and
negative predictive value to detect malignancy in enlarged MLN
was 96% (95% confidence interval [CI], 87–99) and 67% (95% CI,
29–92), respectively. The sensitivity and negative predictive value
of EUS-FNA in small MLN was 93% (95% CI, 66–99) and 92%
(95% CI, 61–99), respectively. EUS-FNA prevented a surgical
(mediastinal) intervention in 88 and 52% of the patients with
enlarged or small MLN, respectively (p  0.001).
Conclusions: As the sensitivity to detect malignant MLN invasion
is comparably high for both enlarged and small but suspected MLN,
clinicians should consider EUS-FNA even in case computed tomog-
raphy-scan shows no enlarged MLN. The impact of EUS-FNA to
avoid surgical mediastinal interventions is greater when enlarged
MLN are present. The moderate negative predictive value of EUS-
FNA makes surgical-pathologic verification still compulsory, re-
gardless of the size of the MLN.
Key Words: Lung cancer, Mediastinal lymph nodes, Endoscopic
ultrasound, EUS-FNA.
(J Thorac Oncol. 2008;3: 245–249)
In non-small cell lung cancer, accurate staging of the medi-astinal lymph nodes (MLN) allows the selection of those
patients who are candidates for radical resection.1,2 Although
imaging techniques such as computed tomography (CT) and
fluorodeoxyglucose positron emission tomography (FDG-
PET) with or without integrated CT scan contribute to me-
diastinal staging, their diagnostic performance is insufficient
to make invasive staging redundant.1,3–5 By consequence,
accurate mediastinal staging requires tissue biopsy in case of
either enlarged or FDG-avid MLN but also in some specific
conditions such as centrally located tumors abutting the
mediastinum, broncho-alveolar cell carcinoma and non–
FDG-avid primary lung tumors.2 Surgical staging procedures
such as cervical mediastinoscopy or video-assisted thoracos-
copy are widely used to obtain MLN biopsies for staging. In
addition to surgical procedures, minimally invasive out-patient
endoscopy techniques have in recent years become available,
allowing the investigation of MLN; in particular, linear transoe-
sophageal endoscopic ultrasound with fine-needle aspiration
(EUS-FNA) and endobronchial ultrasound with transbronchial-
needle aspiration.6,7 These minimally invasive techniques are
now also accepted as mediastinal staging tools.2 This recom-
mendation is based on the substantial amount of nonrandomized
data suggesting that in selected patients with enlarged MLN,
EUS-FNA has a sufficiently high yield (90%) to confirm
MLN involvement.6,8–10 Series addressing the accuracy of EUS-
FNA in lung cancer patients presenting with small but otherwise
suspicious MLN are scarce.
This report studies the diagnostic performance and the
clinical impact of EUS-FNA in a homogenous cohort of lung
cancer patients, according to the size of the MLN.
PATIENTS AND METHODS
Patients and Study Design
We did a retrospective study of a prospectively gath-
ered cohort and analyzed with EUS-FNA 100 lung cancer
patients, all with suspicion of malignant MLN invasion. This
suspicion was based on the fact that enlarged MLN were
found on the CT-scan (short axis 10 mm) or if the patient
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had MLN that were FDG-avid on the PET scan regardless the
MLN size, or if one or more of the following presentations
were present: a primary tumor without FDG uptake, presence
of FDG uptake in hilar lymph nodes, or when the primary
tumor was located in the inner third of the lung (in the
vicinity of the mediastinum—regardless the FDG-PET data).
The FDG-PET data available in this study are heterogenous
because the patients in this study were recruited from over 20
referring hospitals.
The null-hypothesis was that the test characteristics and
the impact of EUS-FNA would not be influenced by the size
of the MLN. The study was registered (B67020072199) and
approved by the local ethics committee of the Ghent Univer-
sity Hospital (Trial Nr EC UZG 193).
If no enlarged MLN were seen on CT-scan, the patient
was categorized in the group with small-sized MLN (group A).
If the short axis of at least one MLN on CT was at least 10 mm,
the patient was categorized as having enlarged MLN (group B).
EUS-FNA was performed by a trained operator
(K.G.T.) in an outpatient setting, using the curved linear
scanning ultrasound endoscope (GF-UCT160-OL5, Olym-
pus, Aartselaar, Belgium) that was connected to the ultra-
sound unit (ALOKA, Mechelen, Belgium).10 There was mon-
itoring of heart rate and oxygen saturation.11 Punctures were
performed with a 22-gauge fine needle (EUS-needle, Olym-
pus, Aartselaar, Belgium). Smears of the aspirates obtained
by EUS-FNA were processed for rapid on site evaluation
(ROSE) to evaluate the cellular contents of the air-dried speci-
mens with a quick staining method (Diff-Quick). If necessary,
several lymph nodes were sampled. Specimens were categorized
positive (tumor cells) or negative (lymphoid but no tumor cells).
Punctures were continued until the cytopathologist (L.V.W.)
was able to make a formal conclusion. As such, representative
MLN sampling was available for all patients.
All 100 patients would routinely have been scheduled
for further invasive diagnostic or staging surgical procedures
targeting the MLN. Only those patients in whom EUS-FNA
did not confirm malignant MLN invasion were referred to the
thoracic surgeon (primarily for cervical mediastinoscopy,
with a systematic sampling of 2R/L-4R/L and 7). If a patient
was operable and when the tumor was resectable, a thoracot-
omy with MLN dissection was performed.12 Hence, a formal
pathology of the MLN investigated with EUS-FNA was
available for all patients.
Statistical Analysis
All categorical variables are reported as proportions.
Continuous variables are reported as medians with mini-
mum–maximum range and are compared with the Mann-
Whitney U test. Diagnostic performance of EUS-FNA and
FDG-PET, calculated at the patient level and defined in terms
of sensitivity and specificity, are estimated accordingly in the
group of 100 patients in whom a formal pathologic diagnosis
was available. The test-characteristics are given with 95%
confidence intervals (CIs) and are analyzed with the Fishers’
exact test. The clinical impact was calculated as the propor-
tion of patients in whom EUS-FNA demonstrated malignant
MLN disease, making a surgical approach of the MLN
redundant. The significance level was set at   0.05. The
analysis was done using SPSS 15.0 (SPSS Inc., Chicago, IL).
RESULTS
Table 1 shows the characteristics of the 100 lung cancer
patients, all with suspicion of malignant MLN invasion and in
whom a formal pathologic diagnosis of the MLN was avail-
able. Twenty-five patients (25%) had only small-sized MLN
on CT and were categorized in group A, whereas 75 patients
(75%) had at least one enlarged MLN and were categorized in
group B. In 41%, a diagnosis of the primary cancer was
available before the EUS-FNA procedure. As such, EUS-
FNA was performed for staging only in 56% versus 36% of
group A and group B patients, respectively (p  0.10). The
overall histology subtype distribution of the primary lung
tumor was comparable between group A and group B. The
median duration of the EUS-FNA procedure, the dose of
sedation, and the number of EUS-FNA passes were compa-
rable between two groups.
FDG-PET data were available for 69 patients (69%)
and suspicion of MLN invasion was noted in 56 patients
(81%). Of group A, 17 patients (85%) had positive or inde-
terminate MLN by FDG-PET versus 46 of the patients (94%)
TABLE 1. Characteristics of the Study Population
All* Group A Group B
Number of patients (n) 100 (100) 25 (25) 75 (75)
Median age (yr; range) 65 (41–84) 68 (51–79) 64 (41–84)
Gender n (%)
Male 77 (77) 22 (88) 55 (73)
Female 23 (23) 3 (12) 20 (27)
Tumor pathology type n (%)
Squamous cell carcinoma 32 (32) 12 (48) 20 (27)
Non-squamous cell
carcinoma
64 (64) 13 (52) 51 (68)
Small cell carcinoma 4 (4) 0 (0) 4 (5)
PET-scan n (%)† 69 (69) 20 (80) 49 (65)
No FDG uptake in MLN 6 (9) 3 (15) 3 (6)
FDG uptake in MLN 56 (81) 12 (60) 44 (90)
Indeterminate visual
correlation
7 (10) 5 (25) 2 (4)
Median procedure duration
in min (range)
30 (15–90) 35 (20–70) 30 (15–90)
Median midazolam doses in
mg (range)
0.0 (0.0–7.5) 0.0 (0.0–3.0) 0.0 (0.0–7.5)
Median number of EUS-
passes (range)
5 (1–12) 5 (2–10) 5 (1–12)
Group A: patients with only small sized MLN (short axis 10 mm measured on
CT); group B: patients with at least one enlarged MLN.
*From the 100 patients, there was one with small MLN on CT that were discretely
enlarged on examination with EUS-FNA, while inversely 2 had on the CT scan an
enlarged MLN that appeared on EUS-FNA to be a conglomerate of several subcentri-
metic lymph nodes. In all other patients, EUS-FNA and CT classifications agreed.
†Fluoro-deoxyglucose-positron emission tomography (FDG-PET) was negative,
positive or indeterminate for MLN invasion. The FDG-PET was scored negative in case
there was no FDG-uptake evidenced in the MLN. The FDG-PET was positive when
there was an unequivocal FDG uptake in at least one MLN (by means of visual
correlation of CT and PET images). The FDG-PET was indeterminate in case no
judgment could be made because of a centrally located tumor, or when the primary
tumor did not uptake FDG or when hilar but not MLN were FDG avid.
MLN, mediastinal lymph nodes.
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of group B (p  0.31; Table 1). The remaining eight patients
of group A with a distinct negative FDG-PET or in whom no
FDG-PET was performed were suspected to have MLN
invasion mainly because the primary lung tumor was in the
vicinity of the mediastinum. All patients of group B under-
went EUS-FNA because there was at least one enlarged MLN
(regardless of the PET data).
On the basis of the unequivocal presence of FDG
uptake in discrete MLN, the sensitivity of FDG-PET to
predict malignant MLN invasion was 78% (95% CI, 39–97)
for group A versus 95% (95% CI, 83–99) for group B (p 
0.14). The accuracy of FDG-PET was 53 and 87% for the
respective groups (p  0.001).
EUS-FNA data are presented in Figure 1. The overall
sensitivity of EUS-FNA was 95% (95% CI, 88–98) with a
corresponding negative predictive value (NPV) of 81% (95%
CI, 58–94). In the 25 patients of group A, the median size of
largest MLN was 7 mm; whereas this was 18 mm in the
patients of group B. The prevalence of malignant MLN
invasion was 56 versus 92% (p  0.001) in the respective
groups. The sensitivity of EUS-FNA to detect malignancy is
93% (95% CI, 66–99) in group A patients versus 96% (95%
CI, 87–99) for group B (p  0.53). This reflects in NPVs of
92% (95% CI, 61–99) and 67% (95% CI, 29–92), respec-
tively, for both groups (p  0.27). The clinical impact in
terms of avoided surgical procedures is 52% for the patients
of group A versus 88% for group B (p  0.001).
In Table 2, the final pathology data of the MLN are
shown. There was no difference in the distribution of histol-
ogy subtypes of the malignant MLN between both studied
groups. All 21 patients in whom EUS-FNA did not demon-
strate malignant MLN invasion were investigated by ensuing
surgical procedures targeting the MLN. Seventeen of these
patients had N0-1 by surgical staging. In four patients, sur-
gical staging showed malignant MLN invasion: one by me-
diastinoscopy (station 7, enlarged MLN, FDG-avid), one by
video-assisted thoracoscopy (station 5, enlarged MLN, FDG-
avid), and two by thoracotomy (station 7, enlarged MLN but
no FDG uptake and station 4L-5, small MLN but intense
FDG uptake). In two of the false negative findings, the
surgical specimen showed a discrete tumor infiltration of
MLN in the subcapsular sinus (Figure 2), whereas in the
other, the malignant infiltration was massive (including the
patient from group A).
DISCUSSION
This study shows that the sensitivity of ROSE-assisted
EUS-FNA to detect malignant MLN in patients with lung cancer
is high, not only for enlarged MLN but also for small MLN. The
impact of EUS-FNA to avoid surgical mediastinal investigation
is however greater when enlarged MLN are present.
In the absence of distant metastasis, the accurate me-
diastinal staging in patients with lung cancer determines both
prognosis and treatment options.13 It was previously shown
that the likelihood of metastases increases with MLN size
measured on CT-scan.3,14 Although at a cut-off of 1 cm
transversal diameter, the best accuracy was found, it was
recognized that up to 33% of the MLN measuring over 3 cm
did not have metastasis, and inversely, that 13% of the
subcentrimetric MLN were metastatic.3 In addition, Seely et
al.15 showed that in patients with T1 lesions and nodes with
a short axis 1cm at CT-scan, 21% had malignant nodal
invasion. The accuracy of FDG-PET/CT scan to predict on
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FIGURE 1. Yield and impact of EUS-FNA in lung cancer pa-
tients. Patient flow chart. Patients were allocated to group A
when no enlarged MLN were seen on the CT scan. Patients
were allocated to group B when at least one enlarged (short
axis at least 10 mm) MLN was seen on the CT scan. All pa-
tients underwent EUS-FNA and in case no malignancy was
shown in the MLN, a referral for surgical mediastinal explo-
ration followed (mainly cervical mediastinoscopy). The prev-
alence of N2/N3 is shown in the upper left corner of the
cross-tables (p  0.001 group A versus B). Test characteris-
tics including sensitivity and NPV do not differ between
groups A and B. Avoided surgery for mediastinal exploration
was statistically higher in group B (p  0.001). MLN, medi-
astinal lymph nodes; Se, sensitivity; Sp, specificity; PPV, posi-
tive predictive value; NPV, negative predictive value. Values
given as percent with (95% CI).
TABLE 2. Final Pathology Diagnosis of the MLN
All Group A Group B
Patients (n) 100 25 75
Malignant MLN (N2/N3); n (%) 83 (83) 14 (56) 69 (92)*
Squamous cell carcinoma 21 (21) 4 (16) 17 (23)
Non-squamous cell carcinoma 58 (58) 10 (40) 48 (64)
Small cell carcinoma 4 (4) 0 (0) 4 (5)
No malignant MLN (N0/N1); n (%) 17 (17) 11 (44) 6 (8)
Group A: patients with only small sized MLN (short axis 10 mm measured on
CT); group B: patients with at least one enlarged MLN.
*p  0.001 group A vs. B.
MLN, mediastinal lymph nodes.
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the presence or absence of malignancy in the MLN is signif-
icantly higher when compared with the CT-scan.4 Neverthe-
less, FDG-PET/CT is more sensitive but less specific with
increasing lymph node size.4,16 The sensitivity of FDG-
PET/CT to detect invasion in small MLN averages only
82%.4 These data challenge the statement that based on FDG
uptake, one can confidently predict on the presence or ab-
sence of malignant invasion, even in small MLN.
The ability of EUS-FNA to contribute to the diagnosis and
staging of lung cancer is now well established based on several
observational series.6,9,10,17–19 Its sensitivity ranges between 77
and 100% and depends on the prevalence of invasion in enlarged
MLN.6 EUS-FNA impacts on the diagnostic decision in a
substantial number of patients since surgical procedures can be
cancelled in 49 to 70%.6,8,10,20,21 These data have recently been
strengthened by a randomized controlled trial that directly com-
pared surgical staging with EUS-FNA.22
It remains however unknown whether the accuracy
reported for EUS-FNA in lung cancer patients with enlarged
MLN can be inferred to patients without enlarged MLN.8
EUS-FNA could be prone to false-negative findings because
it is technically easier to puncture enlarged MLN. Two
reports have analyzed the yield of EUS-FNA in patients in
whom the CT-scan showed no enlarged MLN at all.23,24 The
sensitivity of EUS-FNA ranges in these series from 29 to
61%.23,24 The data also indicate that EUS-FNA detects un-
expected locally advanced disease in 23% of the patients24
and impacts on the clinical management in 36%.23
The current series is the first to compare directly the
yield and impact of EUS-FNA in lung cancer patients with
either small or enlarged MLN. The results indicate that the
sensitivity to detect malignancy in small MLN is not different
as compared with enlarged MLN. The impact in terms of
avoided surgical staging procedures is higher in patients with
enlarged MLN as compared with the patients in whom only
small MLN were found. The clinical impact in the latter
group is however higher than what would be expected based
on the available data.23,24 Several factors can explain this:
first, the patients in this study were selected based on the a
priori clinical suspicion for MLN invasion and by consequence
on the high prevalence of MLN invasion. Second, the data are
biased by that all patients had MLN within reach of EUS-FNA.
This series includes no patients with suspicious MLN located
solely in the pretracheal (4R) or on the aortic arch (region 6).
Third, we10 and others8,25 believe that ROSE during EUS-FNA
enhances the yield because the chance of having inconclusive
samples is likely to be much higher in small MLN.
An important issue is also the value of a negative
finding and the inherent decision whether additional confir-
matory procedures are necessary. EUS-FNA punctures can be
false negative despite the representativity assured by ROSE.
The first reason is of course that the wrong MLN is sampled
(i.e., anatomic miss). We document here that discrete tumor
infiltration in the subcapsular sinuses is another reason. In
those cases, it is obvious that a fine-needle microbiopsy has a
great chance to miss those tumor islets. We found that the
NPV of EUS-FNA was 81%, with a range for enlarged and
small MLN between 67 and 92%. This confirms that, even in
the presence of ROSE, a negative result should always be
confirmed by a surgical procedure.
Although it was shown that invasive staging techniques
have a better test performance as compared with imaging
techniques,5 we analyzed in addition the performance of
FDG-PET as function of the size of the MLN. The overall
sensitivity to detect malignant invasion MLN was 92% in our
series, which largely compares with the values available in a
meta-analysis on FDG-PET-scan accuracy.4 The sensitivity
also tended to be higher for enlarged MLN. The specificity
and accuracy was however low, which can be attributed to the
small patient numbers, the low threshold for suspicion of
MLN invasion and to the exclusion of patients with an indeter-
minate FDG-PET result. Technical factors also could have
FIGURE 2. EUS-FNA and corresponding surgico-pathologic verification. Left panel, EUS-FNA of MLN 4L (aorto-pulmonary
window). The fine needle is placed into the center of the MLN. The cytology of the fine-needle aspiration was negative. Right
panel, Surgico-pathologic verification by mediastinoscopy. The normal parenchyma of the MLN is characterized by lympho-
cytes (deep purple dots) and antraco-silicotic pigment in the macrophages (dark brown color). In the right upper corner (ar-
row), a discrete but clear solitary tumor islet is present, situated in the subcapsular sinusoidal space of the MLN (H&E staining;
magnification 200).
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contributed since the FDG-PET data were obtained from differ-
ent hospitals. Nevertheless, the data show that mediastinal stag-
ing based solely on FDG-PET data remains unreliable.5
We conclude that the sensitivity to detect malignant
MLN invasion is comparably high for both enlarged and
small MLN. Hence, the clinician should consider EUS-FNA,
even if otherwise suspicious MLN are not enlarged on CT.
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